Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International multicenter open-label trial for pediatric AML
DRKS00024079Phase 3Recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Oct 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label trial of cytarabine, idarubicin, etoposide, mitoxantrone, fludarabine and 6 more in acute myeloid leukemia (AML) (3 arms), sponsored by German Society for Pediatric Oncology and Hematology. Started Oct 2022; status: recruiting.
02
Drugs
cytarabineidarubicinetoposidemitoxantronefludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00024079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00024079.